Advertisement

Phospholipid inhibitors

Journal: Hämostaseologie
ISSN: 0720-9355
Topic:

55. GTH-Jahrestagung
Onkopedia-Leitlinie

DOI: http://dx.doi.org/10.5482/ha-1165
Issue: Issues of 2011 (Vol. 31): Issue 4 2011 (225-312)
Pages: 243-250

Phospholipid inhibitors

State of the Art

M. Galli (1)

(1) Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy

Keywords

thrombosis, abortion, antiphospholipid syndrome, Antiphospholipid antibodies

Summary

The antiphospholipid syndrome (APS) is defined by the association of arterial and/or venous thrombosis and/or pregnancy complications with the presence of at least one among the main antiphospholipid antibodies (aPL) (i. e., Lupus anticoagulants, LA, IgG and/or IgM anticardiolipin antibodies, aCL, IgG and/or IgM antiβ2-glycoprotein I antibodies, aβ2-GPI). Several clinical studies have consistently reported that LA is a stronger risk factor for both arterial and venous thrombosis compared to aCL and aβ2-GPI. In particular, LA activity dependent on the first domain of β2-GPI and triple aPL positivity are associated with the risk of thrombosis and obstetrical complications. Asymptomatic aPL-positive subjects do not require primary thromboprophylaxis. Venous thromboembolism is the most common initial clinical manifestation of APS. To prevent its recurrence indefinite anticoagulation is recommended. Long duration treatment with warfarin or aspirin is used after a first cerebral arterial thrombosis. Low molecular weight heparin (LMWH) with or without aspirin is recommended to reduce the rate of obstetrical complications of APS pregnant women.

You may also be interested in...

1.
Marielle Sanmarco1, Stéphane Gayet1, Marie-Christine Alessi2, Marie Audrain3, Emmanuel de Maistre4, Jean-Christophe Gris5, Philip G. de Groot6, Eric Hachulla7, Jean-Robert Harlé1, Pierre Sié8, Marie-Claire Boffa9

Thromb Haemost 2007 97 6: 949-954

http://dx.doi.org/10.1160/TH06-10-0604

2.
F. Bergmann, M. Hempel

Hämostaseologie 2008 28 3: 141-149

3.
A European multicentre retrospective study

A. Ruffatti (1), E. Salvan (1), T. Del Ross (1), M. Gerosa (2), L. Andreoli (3), A. Maina (4), J. Alijotas-Reig (5), S. De Carolis (6), A. Mekinian (7), M. T. Bertero (8), V. Canti (9), A. Brucato (10), K. Bremme (11), V. Ramoni (12), M. Mosca (13), E. Di Poi (14), P. Caramaschi (15), M. Galeazzi (16), A. Tincani (3), P. L. Meroni (2)

Thromb Haemost 2014 112: -

http://dx.doi.org/10.1160/TH14-03-0191